Amneal Pharmaceuticals Inc (AMRX) |
|
5.21 -0.21 (-3.87%)
|
10-23 23:45 |
|
Open: |
5.43 |
Pre. Close: |
5.42 |
|
High:
|
5.51 |
Low:
|
5.16 |
|
Volume:
|
947,392 |
Market Cap:
|
769M |
|
|
|
|
Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 6,000 full-time employees. The firm is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. The company operates in two segments, which include Generics and Specialty Pharma. The Generics is focused on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their drug names. The Specialty Pharma is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease (PD), post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.514 - 5.542 |
5.542 - 5.56 |
|
Low:
|
5.096 - 5.132 |
5.132 - 5.154 |
|
Close:
|
5.159 - 5.213 |
5.213 - 5.247 |
|
Technical analysis |
as of: 2020-10-23 4:40:33 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 6.44  One year: 7.52 |
| Support: |
Support1: 4.43 Support2: 3.76 |
| Resistance: |
Resistance1: 5.51 Resistance2: 6.44 |
| Pivot: |
4.86 |
| Moving Average: |
MA(5): 5.26 MA(20): 4.63
MA(100): 4.46 MA(250): 4.16 |
| MACD: |
MACD(12,26): 0.32 Signal(9): 0.25 |
| Stochastic oscillator: |
%K(14,3): 86.87 %D(3): 85.97 |
| RSI: |
RSI(14): 68.07 |
| 52-week: |
High: 5.79 Low: 2.40 Change(%): 62.8 |
| Average Vol(K): |
3-Month: 114214 10-Days: 124169 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.AMRX has closed below upper band by 27.8%. Bollinger Bands are 60% wider than normal. The large width of the bands suggest high volatility as compared to AMRX's normal range. The bands have been in this wide range for 8 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Fri, 23 Oct 2020
How Will the Market React to Amneal Pharmaceuticals Inc (AMRX) Stock Getting a Bullish Rating - InvestorsObserver
Thu, 22 Oct 2020
SVB Leerink Weighs in on Amneal Pharmaceuticals, Inc.'s Q3 2020 Earnings (NYSE:AMRX) - MarketBeat
Thu, 22 Oct 2020
A Look At The Behavior Of Amneal Pharmaceuticals, Inc. (AMRX) Stock - Stocks Register
Wed, 21 Oct 2020
Is Amneal Pharmaceuticals Inc. [AMRX] Stock Is Still Just for Futuristic Bulls at this Point? - MZP News
Wed, 21 Oct 2020
Do Analysts Expect Amneal Pharmaceuticals Inc (AMRX) Stock to Rise? - InvestorsObserver
Wed, 21 Oct 2020
Is Amneal Pharmaceuticals Inc. (AMRX) a Keeper? - The News Heater
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers General Specialty & Generic |
| Shares Out. (M) |
148 |
| Shares Float (M) |
94 |
|
% Held by Insiders
|
10.36 |
|
% Held by Institutions
|
69.44 |
|
Shares Short (K)
|
7,510 |
|
Shares Short P. Month (K)
|
6,920 |
Stock Financials |
|
EPS
|
-1.371 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
2.080 |
|
Profit Margin
|
-11.16 |
|
Operating Margin
|
6.85 |
|
Return on Assets (ttm)
|
1.8 |
|
Return on Equity (ttm)
|
-58.4 |
|
Qtrly Rev. Growth
|
14.8 |
|
Gross Profit (p.s.)
|
3.368 |
|
Sales Per Share
|
11.793 |
|
EBITDA (p.s.)
|
2.325 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
317 |
|
Levered Free Cash Flow (M)
|
213 |
Stock Valuations |
|
PE Ratio
|
-3.80 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.50 |
|
Price to Sales
|
0.44 |
|
Price to Cash Flow
|
2.42 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
